Skip to main content
DXCMDexCom, Inc.Buy Wait6.2·$89.39-0.33%

DexCom (DXCM) Q2 2026 earnings — TrendMatrix coverage

BEAT+15.1% vs estimateEPS $0.70 vs $0.61 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.70
Estimate
$0.61
Surprise
+15.1%
Revenue (period 2026-06-30)
$1.31B
Score at report (before → after)
6.66.7/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

DexCom (DXCM) beat the $0.61 estimate with diluted EPS of $0.70 — a large 15.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.6/10) to Hold at 6.7/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates DXCM Buy (Wait) at 6.2/10.

4 of the last 4 quarters beat the estimate; this quarter's +15.1% surprise compares with a +11.5% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.5 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Product: CGM systems
  • Concentration risk — Supplier: single- or sole-source suppliers
  • Analyst target reached - limited upside remaining

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$89.39
Entry target
$73.98
Price target
$103.17
Stop
$69.33
Upside to target
+15.4%

The stock trades at 35.5× trailing but 28.7× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

DXCM at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Devices
Market cap
$33.85B
P/E (fwd)
28.7
P/E (ttm)
35.5
52-week range
$54.11$92.59
Off 52-week high
3.5%
RSI (14)
50
Volume vs avg
0.40×
Score today
6.2/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks DXCM Earnings Q2 2026 earnings